FUB-PB-22

FUB-PB-22 (QUFUBIC) is an indole-based synthetic cannabinoid that is a potent agonist of the CB₁ receptor and has been sold online as a designer drug.[1][2]

FUB-PB-22

Legal status
Legal status	CA: Schedule II DE: Anlage II (Authorized trade only, not prescriptible) UK: Class B
Identifiers
IUPAC name quinolin-8-yl 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylate
CAS Number	1800098-36-5
PubChem CID	91936864
ChemSpider	29763736
UNII	DS46154N3F
Chemical and physical data
Formula	C25H17FN2O2
Molar mass	396.421 g·mol^−1
3D model (JSmol)	Interactive image
SMILES Fc1ccc(cc1)Cn1cc(c2c1cccc2)C(=O)Oc1cccc2c1nccc2
InChI InChI=1S/C25H17FN2O2/c26-19-12-10-17(11-13-19)15-28-16-21(20-7-1-2-8-22(20)28)25(29)30-23-9-3-5-18-6-4-14-27-24(18)23/h1-14,16H,15H2 Key:ROHVURVXAOMRJY-UHFFFAOYSA-N

Pharmacology

FUB-PB-22 acts as a full agonist with a binding affinity of 0.386nM at CB₁ and 0.478nM at CB₂ cannabinoid receptors.[3]

Legal status

FUB-PB-22 is an Anlage II controlled substance in Germany. It was scheduled in Japan in July 2014.

As of October 2015 FUB-PB-22 is a controlled substance in China.[4]

It is also banned in Sweden.[5]

See also

• 2F-QMPSB
• 5F-PB-22
• AM-2201
• BB-22
• FUB-JWH-018
• AB-FUBINACA
• ADB-FUBINACA
• AMB-FUBINACA
• FDU-PB-22
• FUB-144
• FUB-APINACA
• MDMB-FUBICA
• MDMB-FUBINACA
• PB-22

References

1. "FUB-PB-22". Southern Association of Forensic Scientists. Archived from the original on 27 May 2015. Retrieved 23 July 2015.
2. Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, Hakamatsuka T (February 2015). "N-OH-EDMA, and a cathinone derivative dimethoxy-α-PHP, newly identified in illegal products". Forensic Toxicology. 33 (2): 244–259. doi:10.1007/s11419-015-0268-7. PMC 4525202. PMID 26257833.
3. Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (1 July 2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. PMC 4929166. PMID 27429655.
4. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
5. "Cannabinoider föreslås bli klassificerade som hälsofarlig vara". Folkhälsomyndigheten. 28 May 2014. Retrieved 23 July 2015.